The Efficacy and Safety of Tofacitinib in 48 Children and Adolescents With Alopecia Areata: A Retrospective Study From China

A single‐center retrospective study evaluated tofacitinib in 48 Chinese children and adolescents (aged 2–18 years) with alopecia areata. At Week 12, the median relative improvement rate in SALT score from baseline was 50.0% (IQR: 27.2%–70.2%). By Week 24, the improvement increased to 84.3% (IQR: 52.2%–100.0%), and 20 patients (41.7%) achieved SALT 100 complete response and 11 patients (22.9%) attained SALT 75 . During extended follow‐up, 24 patients experienced relapse. Recurrence rates were significantly higher in those with dose reduction or withdrawal (73.1%, 19/26) compared to patients maintaining treatment (31.3%, 5/16). All reported adverse events were mild. Tofacitinib demonstrated efficacy and acceptable safety, but the high recurrence rate underscores the need for long‐term management.